Aspirotx offers reliable WordPress hosting powered by Bluehost, enabling users to launch and manage WordPress sites with built‑in performance and security features. The service also provides domain registration options, allowing customers to secure a web address directly through the platform. Revenue is generated through monthly hosting subscriptions and domain registration fees.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for obstructive lung diseases like COPD and asthma only alleviate symptoms without addressing the underlying causes and disease progression. There is a lack of therapies that can modify the course of these diseases and improve long-term lung function.
Solution
Aspiro Therapeutics is developing peptidomimetic therapies that mimic the protective properties of club cell secretory protein-16 (CC16) to treat and prevent obstructive lung diseases. By mimicking CC16, the peptidomimetic therapy aims to deliver targeted action to improve lung health. The therapy is designed to address the underlying causes of conditions like COPD, asthma, and cystic fibrosis, offering a new approach to improve patient outcomes.
Target Audience
The primary target audience includes individuals suffering from obstructive lung diseases such as COPD, asthma, and cystic fibrosis, as well as healthcare providers and researchers in the field of respiratory medicine.
Features
- Peptidomimetic drugs that mimic the function of the naturally occurring lung protein CC16
- Designed to treat and prevent obstructive lung diseases such as COPD, asthma, and cystic fibrosis
- Aims to modify the natural course of COPD and other obstructive lung diseases
- Preclinical animal models have shown protection from COPD- and asthma-like diseases